Global Contrast-Enhanced Ultrasound Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2033

Contrast-Enhanced Ultrasound Market Size

• The global contrast-enhanced ultrasound market size was valued at USD 1.89 billion in 2025 and is expected to reach USD 2.98 billion by 2033, at a CAGR of 5.88% during the forecast period
• The market growth is largely fueled by the increasing adoption of advanced imaging technologies, rising prevalence of chronic and cardiovascular diseases, and the growing demand for non-invasive, accurate diagnostic tools in both hospitals and outpatient settings
• Furthermore, the rising need for improved lesion detection, enhanced tumor characterization, and better vascular imaging is establishing contrast-enhanced ultrasound (CEUS) as a preferred imaging solution among clinicians. These converging factors are accelerating the uptake of Contrast-Enhanced Ultrasound solutions, thereby significantly boosting the industry's growth globally

Contrast-Enhanced Ultrasound Market Analysis

• Contrast-enhanced ultrasound (CEUS), providing real-time imaging with enhanced lesion and vascular visualization, is increasingly vital in both diagnostic and interventional procedures across hospitals, outpatient clinics, and specialty imaging centers due to its non-invasive nature, high accuracy, and safety profile
• The escalating demand for CEUS is primarily fueled by the growing prevalence of cardiovascular diseases, cancer diagnostics, liver and kidney disorders, and the rising adoption of advanced imaging technologies in healthcare facilities
• North America dominated the contrast-enhanced ultrasound market with the largest revenue share of approximately 39.5% in 2025, supported by a well-established healthcare infrastructure, early adoption of advanced imaging solutions, and strong presence of key industry players. The U.S. experienced substantial growth in CEUS applications due to increasing use in oncology and cardiology diagnostics, technological innovations, and ongoing clinical research initiatives
• Asia-Pacific is expected to be the fastest-growing region in the contrast-enhanced ultrasound market during the forecast period, registering a CAGR of around 11.2%, driven by rising healthcare expenditure, expanding medical imaging infrastructure, increasing incidence of chronic diseases, and growing awareness of non-invasive diagnostic techniques in countries such as China, Japan, and India
• The Non-Targeted CEUS segment accounted for the largest market revenue share of 62.1% in 2025, driven by its extensive applicability in general diagnostics, including liver, cardiac, and vascular imaging

Report Scope and Contrast-Enhanced Ultrasound Market Segmentation     

Contrast-Enhanced Ultrasound Market Trends

Increasing Adoption of Advanced Imaging Techniques

• A significant and accelerating trend in the global contrast-enhanced ultrasound (CEUS) market is the growing adoption of advanced ultrasound imaging techniques for diagnostic and interventional procedures. Healthcare providers are increasingly preferring CEUS over traditional imaging modalities due to its real-time imaging capabilities, safety profile, and non-invasive nature
• CEUS enables enhanced visualization of tissue perfusion, vascular structures, and lesion characterization without the risks associated with ionizing radiation, making it highly valuable in cardiology, oncology, and hepatology applications
  • For instance, in Europe, hospitals such as Charité – Universitätsmedizin Berlin have successfully implemented CEUS for liver tumor detection, significantly improving diagnostic accuracy compared to conventional ultrasound
• Furthermore, the development of specialized contrast agents with improved stability and enhanced imaging resolution is expanding the clinical utility of CEUS, enabling more accurate diagnostics in complex cases such as liver tumors, kidney lesions, and cardiovascular abnormalities
• The growing awareness among clinicians regarding the advantages of CEUS, including faster diagnosis, cost-effectiveness, and reduced patient discomfort, is driving its adoption in both hospital and outpatient care settings worldwide
• Continuous technological advancements, such as portable ultrasound devices and integrated software for better image analysis, are also contributing to the rising popularity of CEUS in emerging markets where accessibility and efficiency are critical

Contrast-Enhanced Ultrasound Market Dynamics

Driver

Rising Incidence of Chronic Diseases and Growing Diagnostic Needs

• The global prevalence of chronic diseases such as cardiovascular disorders, liver diseases, and cancers is significantly driving demand for accurate and timely diagnostic solutions, thereby boosting the CEUS market
• In oncology, CEUS is increasingly used for early detection, lesion characterization, and monitoring treatment response, particularly in liver and breast cancers, supporting better patient outcomes
  • For instance, in 2024, the Royal Free Hospital in London reported improved detection rates of hepatocellular carcinoma using CEUS compared to CT scans in high-risk patients
• Healthcare institutions are investing in CEUS to improve diagnostic workflows, reduce dependency on expensive imaging techniques like CT and MRI, and enhance patient throughput
• Furthermore, increasing government initiatives to improve diagnostic capabilities in emerging economies, combined with rising healthcare expenditure, are further propelling the demand for contrast-enhanced ultrasound technologies globally

Restraint/Challenge

High Cost of Contrast Agents and Limited Awareness in Certain Regions

• Despite its advantages, the relatively high cost of specialized ultrasound contrast agents can be a barrier to widespread adoption, particularly in price-sensitive healthcare settings in developing regions
• In addition, limited awareness among healthcare professionals and patients about the benefits and applications of CEUS can slow market growth, as some clinicians continue to rely on conventional ultrasound or other imaging modalities
  • For instance, in parts of South Asia, several clinics have yet to adopt CEUS due to the lack of trained professionals and insufficient knowledge about its advantages, despite its proven effectiveness in liver and kidney diagnostic
• Another challenge is the regulatory complexity associated with the approval of new contrast agents and imaging systems, which can delay product launches and market entry in certain countries
• Overcoming these challenges through targeted training programs for clinicians, cost-effective solutions, and streamlined regulatory pathways will be vital for sustained growth and broader adoption of CEUS technologies worldwide

Contrast-Enhanced Ultrasound Market Scope

The market is segmented on the basis of product type, technology, and end-users.

• By Product Type

On the basis of product type, the Contrast-Enhanced Ultrasound market is segmented into Equipment and Contrast Agents. The Equipment segment dominated the largest market revenue share of 57.4% in 2025, driven by the rising adoption of advanced ultrasound machines for improved imaging accuracy, particularly in oncology, cardiology, and liver disease diagnostics. Hospitals and diagnostic centers prefer these systems due to their ability to provide real-time visualization, high-resolution images, and compatibility with a range of contrast agents. Investment in healthcare infrastructure, particularly in North America and Europe, further fuels the demand for CEUS equipment. Additionally, the integration of software enhancements, image processing technologies, and supportive government reimbursement policies boosts adoption. Equipment is also favored because of its longer lifecycle, reliability, and capacity to handle multiple imaging applications. The growing number of hospitals and diagnostic centers in emerging economies also contributes to the dominance of this segment globally.

The Contrast Agents segment is expected to witness the fastest CAGR of 10.8% from 2026 to 2033, driven by increasing use in oncology imaging, cardiovascular diagnostics, and liver evaluations. Continuous innovation in microbubble-based and nanoparticle-based contrast agents has enhanced image clarity and diagnostic precision. Regulatory approvals for new contrast agents, rising awareness among healthcare professionals, and the need for non-invasive diagnostic methods further contribute to rapid growth. The adoption of contrast agents is also increasing in emerging markets due to affordability, safety, and effectiveness. Furthermore, growing research on targeted CEUS agents for precision medicine and tumor characterization is accelerating demand. Expansion of outpatient imaging facilities and increased clinical trials using contrast agents are additional growth drivers.

• By Technology

On the basis of technology, the market is segmented into Non-Targeted and Targeted CEUS. The Non-Targeted CEUS segment accounted for the largest market revenue share of 62.1% in 2025, driven by its extensive applicability in general diagnostics, including liver, cardiac, and vascular imaging. Its ease of use, cost-effectiveness, and compatibility with existing ultrasound equipment make it highly preferred among hospitals. Non-targeted CEUS is widely adopted in large hospital chains and diagnostic centers due to lower operational complexity, minimal training requirements, and proven safety profiles. The segment benefits from high patient inflow, supportive healthcare policies, and increasing awareness among clinicians regarding CEUS benefits over traditional imaging techniques. Additionally, non-targeted CEUS provides real-time imaging for routine and emergency diagnostics, which further reinforces its dominant market position globally.

The Targeted CEUS segment is expected to witness the fastest CAGR of 12.5% from 2026 to 2033, fueled by growing use in precision medicine, oncology imaging, and personalized diagnostics. Targeted CEUS enables enhanced visualization of tumors, vascular abnormalities, and inflammatory lesions, providing significant clinical value. The development of novel targeted contrast agents and molecular imaging techniques is driving adoption in specialty hospitals and research institutions. Increasing investment in R&D, clinical trials, and awareness programs for precision diagnostics further accelerate growth. Targeted CEUS is particularly gaining traction in developed countries, while emerging economies are gradually adopting it due to increasing healthcare infrastructure and government support for advanced imaging technologies.

• By End-Users

On the basis of end-users, the market is segmented into Hospitals, Clinics, and Ambulatory Surgical Centres (ASCs). The Hospital segment dominated the largest market revenue share of 68.5% in 2025, owing to the presence of advanced imaging infrastructure, availability of skilled radiologists, and the ability to handle high patient volumes. Hospitals prefer CEUS for its non-invasive nature, high diagnostic accuracy, and wide applicability across oncology, cardiology, and liver imaging. The segment is supported by increased hospital expansions, government healthcare funding, and rising investments in diagnostic imaging facilities. Hospitals also benefit from higher reimbursement coverage for CEUS procedures, driving adoption. The high adoption in North America and Europe is complemented by growing awareness in Asia-Pacific and Latin America. The combination of advanced equipment, trained personnel, and research integration makes hospitals the dominant end-user globally.

The Clinics and Ambulatory Surgical Centres segment is expected to witness the fastest CAGR of 11.2% from 2026 to 2033, driven by the increasing use of CEUS in outpatient diagnostics and minimally invasive procedures. Clinics and ASCs prefer CEUS due to its non-invasive nature, lower procedure costs, and faster results compared to MRI or CT scans. The adoption of portable CEUS equipment allows smaller clinics and ASCs to perform high-quality imaging without requiring full-scale hospital setups. Growing awareness among physicians, technological advancements in compact imaging devices, and increasing outpatient procedures are fueling growth. The rising trend of preventive diagnostics, increasing patient preference for outpatient services, and expansion of imaging services in emerging markets are additional growth drivers supporting the rapid CAGR of this segment.

Contrast-Enhanced Ultrasound Market Regional Analysis

• North America dominated the contrast-enhanced ultrasound market with the largest revenue share of approximately 39.5% in 2025
• Supported by a well-established healthcare infrastructure
• Early adoption of advanced imaging solutions, and a strong presence of key industry players

U.S. Contrast-Enhanced Ultrasound Market Insight
The U.S. contrast-enhanced ultrasound market captured the majority of the North American market revenue in 2025, driven by increasing use of CEUS in oncology and cardiology diagnostics, continuous technological innovations, and ongoing clinical research initiatives. The country’s advanced healthcare system, high adoption of non-invasive imaging techniques, and investments in medical imaging research further fueled market growth.

Europe Contrast-Enhanced Ultrasound Market Insight
The Europe contrast-enhanced ultrasound market is projected to grow at a significant CAGR during the forecast period, fueled by increasing demand for advanced diagnostic imaging solutions and improvements in healthcare infrastructure. The region’s focus on early detection and minimally invasive procedures is encouraging the adoption of CEUS across hospitals, diagnostic centers, and specialty clinics. The U.K. and Germany are leading contributors, with adoption driven by increasing clinical applications, supportive healthcare policies, and investments in healthcare technology.

U.K. Contrast-Enhanced Ultrasound Market Insight
The U.K. contrast-enhanced ultrasound market is expected to witness steady growth, driven by a growing focus on non-invasive diagnostic procedures and increasing awareness of CEUS applications in cardiology and oncology. Strong healthcare infrastructure, high patient awareness, and government support for medical imaging technologies are key growth factors.

Germany Contrast-Enhanced Ultrasound Market Insight
Germany’s contrast-enhanced ultrasound market is expected to expand considerably, fueled by advanced healthcare systems, a growing focus on minimally invasive diagnostics, and the integration of CEUS in hospitals and specialized clinics. Investments in clinical research and advanced imaging technologies are further driving adoption.

Asia-Pacific Contrast-Enhanced Ultrasound Market Insight
The Asia-Pacific contrast-enhanced ultrasound market is expected to be the fastest-growing region, registering a CAGR of around 11.2% during the forecast period. Growth is driven by rising healthcare expenditure, expanding medical imaging infrastructure, increasing incidence of chronic diseases, and growing awareness of non-invasive diagnostic techniques. Countries such as China, Japan, and India are at the forefront of market expansion.

Japan Contrast-Enhanced Ultrasound Market Insight
Japan’s contrast-enhanced ultrasound market is growing steadily due to the high adoption of advanced imaging technologies, an aging population requiring non-invasive diagnostics, and the integration of CEUS in clinical and research applications. The country emphasizes early diagnosis and improved patient outcomes, which supports market growth.

China Contrast-Enhanced Ultrasound Market Insight
China contrast-enhanced ultrasound market accounted for the largest market revenue share in Asia-Pacific in 2025, driven by a rapidly expanding healthcare infrastructure, increasing adoption of CEUS in hospitals and diagnostic centers, and high awareness of non-invasive imaging techniques. The government’s push for advanced healthcare services, coupled with rising chronic disease prevalence, is significantly fueling market demand.

Contrast-Enhanced Ultrasound Market Share

The Contrast-Enhanced Ultrasound industry is primarily led by well-established companies, including:

• GE Healthcare (U.S.)
• Siemens Healthineers (Germany)
• Philips Healthcare (Netherlands)
• Canon Medical Systems (Japan)
• Fujifilm Holdings Corporation (Japan)
• Samsung Medison (South Korea)
• Hitachi Medical Systems (Japan)
• Bracco Imaging S.p.A. (Italy)
• Guerbet Group (France)
• Lantheus Medical Imaging (U.S.)
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China)
• Hologic, Inc. (U.S.)
• SonoScape Medical Corp. (China)
• Esaote S.p.A. (Italy)
• OptoSonics Medical, Inc. (U.S.)

Latest Developments in Global Contrast-Enhanced Ultrasound Market

• In April 2023, Bracco Imaging S.p.A., a global leader in diagnostic imaging, entered into an agreement with SonoThera, Inc. under which Bracco provided its gas‑filled microbubble technology platform to support SonoThera’s development of an ultrasound‑guided nonviral gene therapy platform. This collaboration reflects innovative use of CEUS contrast microbubbles beyond traditional imaging into therapeutic and gene delivery research
• In May 2024, Inteleos and the International Contrast Ultrasound Society (ICUS) announced a collaboration to develop a comprehensive education and certification ecosystem for CEUS, aimed at enhancing contrast‑enhanced ultrasound training, skill proficiency, and standards among sonographers and clinicians — supporting broader clinical adoption and competency in CEUS practice
• In March 2024, Samsung Medison and Bracco Imaging signed a Memorandum of Understanding at the European Congress of Radiology to advance diagnostic ultrasound technology and contrast agent utilization, focusing on improving CEUS image resolution and clinical workflow efficiencies
• In November 2024, GE HealthCare received U.S. FDA approval for a pediatric indication for its Optison ultrasound enhancing agent, enabling enhanced diagnostic clarity in echocardiography for children and expanding the clinical utility of contrast ultrasound in pediatric cardiology
• In August 2025, Bracco Imaging’s SonoVue ultrasound contrast agent received clearance from China’s National Medical Products Administration for use in hysterosalpingo contrast sonography (HyCoSy) to evaluate female infertility, expanding CEUS applications into reproductive health diagnostics

SKU-62967